Gastric cancer: Prevention, risk factors and treatment

Gastroenterology and Hepatology from Bed to Bench

Volumn 4, Issue 4, 2011, Pages 175-185

  Zali, Hakimeh ^a   Rezaei Tavirani, Mostafa ^b   Azodi, Mona ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Adenocarcinoma; Gastric carcinoma; Stomach cancer

Indexed keywords

CALGRANULIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; MITOMYCIN; PACLITAXEL;

BLOOD CELL COUNT; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CAUSE OF DEATH; DEMOGRAPHY; DIET THERAPY; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; ESOPHAGOGASTRODUODENOSCOPY; ETHNICITY; GASTRECTOMY; HEREDITY; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PROGNOSIS; REVIEW; RISK FACTOR; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH LYMPHOMA; SYMPTOMATOLOGY; UNDIFFERENTIATED CARCINOMA;

EID: 80053392326     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Rustgi AK. Neoplasms of the stomach. In: Goldman L, Ausiello D, eds. Cecil medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007.
2. Gunderson LL, Donohue JH, Alberts SR. Cancer of the stomach. In: Abeloff MD, et al., eds. Abeloff's clinical oncology. 4th ed. Philadelphia, PA: Saunders Elsevier; 2008.
3. National Cancer Institute. Gastric cancer treatment PDQ. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/gastric/HealthProfessional/page1. Updated July 8, 2010.
4. Derakhshan MH, Yazdanbod A, Sadjadi AR, Shokoohi B, McColl KEL, Malekzadeh, R. High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran. Gut 2004; 53:1262-66.
5. Fan XM, Wong BCY, Wang WP, Zhow XM, Cho CH, Yuen ST, et al. Inhibition of proteosome function induced apoptosis in gastric cancer. Int J Cancer 2001;93: 481-88.
6. Holian O, Wahid S, Atten MJ, Attar BM. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am J Physiol Gastrointest Liver Physiol 2002; 282: 809-16.
7. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through upregulation of bax and bak. Carcinogenesis 2001; 22:1393-97.
8. Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of helicobacter pylori infection combined with cagA and pepsinogen status on gastric cancer development among Japanese men and women: A nested case-control study. Cancer Epidemiol. Biomarkers Prev 2006; 15: 1341-47.
9. Otaka M, Konishi N, Odashima M, Jin M, Wada I, Matsuhashi T, et al. Is Mongolian gerbil really adequate host animal for study of Helicobacter pylori infection-induced gastritis and cancer? Biochem Biophys Res Commun 2006; 347: 297-300.
10. Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, et al. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn J Cancer Res 1996; 87: 1263-70.
11. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88: 921-32.
12. Lai JF, Kim S, Li C. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol 2008; 15: 1464-69.
13. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, et al. Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 2006; 47: 2140-46.
14. He YT, Hou J, Chen ZF. Trends in incidence of esophageal and gastric cardia cancer in highrisk areas in China. Eur J Cancer Prev 2008; 17: 71-76.
15. Maeda H, Okabayashi T, Nishimori I. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach. J Am Coll Surg 2008; 206: 306-10.
16. Adachi Y, Mori M, Tsuneyoshi M. Benign gastric ulcer grossly resembling a malignancy: a clinicopathological study of 20 resected cases. J Clin Gastroenterol 1993; 16: 103-108.
17. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinaltypecarcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64:31-49.
18. Ming SC. Gastric carcinoma: a pathobiological classification. Cancer 1977; 39: 2475-85.
19. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol 2006; 20: 651-74.
20. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136: 521-38.
21. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991; 101: 1159-70.
22. Hundahl SA, Phillips JL, and Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000; 88: 921-32.
23. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735-40.
24. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-53.
25. Mirzaee V, Molaee M, Mohaghegh Shalmani H, Zojaji H, Mashayekhi R, Zali MR. Effect of Helicobacter pylori infection on the expression of DNA Mismatch Repair Protein. Gastroenterol Hepatol Bed Bench. 2008;1(1):33-38
26. Parsonnet J, Friedman GD, Vandersteen DP. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
27. El-Omar EM, Carrington M, Chow WH. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
28. Rad R, Dossumbekova A, Neu B. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut 2004; 53: 1082-89.
29. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-43.
30. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia:a prospective cohort study. Gut 2007; 56: 1503-11.
31. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005; 16: 285-94.
32. Haenszel W, Correa P, Cuello C. Gastric cancer in Colombia. II. Case-control epidemiologic study of precursor lesions. J Natl Cancer Inst 1976; 57: 1021-26.
33. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2009; 59: 71-96.
34. Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence andincidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol 2007; 37: 884-91.
35. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 1994; 106: 1584-88.
36. Ilyas M, Tomlinson IP. The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J Pathol 1997; 182: 128-37.
37. Brooks-Wilson AR, Kaurah P, Suriano G. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41: 508-17.
38. Guilford P, Hopkins J, Harraway J. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
39. Robertson EV and Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol 2008; 103: 443-49.
40. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006; 14: 21-33.
41. McKie AB, Filipe MI, Lemoine NR. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993; 55: 598-603.
42. Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72: 565-73.
43. Ladeiras-Lopes R, Pereira AK, Nogueira A. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008; 19: 689-701.
44. Engel LS, Chow WH, Vaughan TL. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1404-13.
45. Ye W, Ekstrom AM, Hansson LE, Bergstrom R, Nyren O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer 1999; 83: 223-29.
46. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85: 340-46.
47. Sjdahl K, Lu Y, Nilsen TI. Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. Int J Cancer 2007; 120: 128-32.
48. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition and Prevention of Cancer: a Global Perspective. Washington, DC: American Institute of Cancer Research; 1997.
49. Gammon MD, Schoenberg JB, Ahsan H. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277-84.
50. Leung WK, Lin SR, Ching JY. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-49.
51. Graham S, Haughey B, Marshall J. Diet in the epidemiology of gastric cancer. Nutr Cancer 1990; 13:19-34.
52. Risch HA, Jain M, Choi NW. Dietary factors and the incidence of cancer of the stomach. Am J Epidemiol 1985; 122: 947-59.
53. Buiatti E, Palli D, Decarli A. A case-control study of gastric cancer and diet in Italy. Int J Cancer 1989; 44: 611-16.
54. Lunet N, Valbuena C, Carneiro F, Lopes C, Barros H. Antioxidant vitamins and risk of gastric cancer: a case-control study in Portugal. Nutr Cancer 2006; 55: 71-77.
55. Ngoan LT, Mizoue T, Fujino Y, Tokui N, Yoshimura T. Dietary factors and stomach cancer mortality. Br J Cancer 2002; 87: 37-42.
56. van den Brandt PA, Botterweck AA, Goldbohm RA. Salt intake, cured meat consumption, refrigerator use and stomach cancer incidence: a prospective cohort study (Netherlands). Cancer Causes Control 2003; 14: 427-38.
57. Buiatti E, Palli D, Decarli A. A case-control study of gastric cancer and diet in Italy: II. Association with nutrients. Int J Cancer 1990; 45: 896-901.
58. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007; 10: 75-83.
59. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007; 56: 1503-11.
60. Farrow DC, Vaughan TL, Hansten PD. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
61. Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch Intern Med 1990; 150: 2022-26.
62. Sauvaget C, Lagarde F, Nagano J, Soda M, Koyama K, Kodama K. Lifestyle factors, radiation and gastric cancer in atomic-bomb survivors (Japan). Cancer Causes Control 2005; 16: 773-80.
63. Correa P, Fontham ET, Bravo JC. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-88.
64. Kubo A, Corley DA. Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol 2007; 102: 2323-30.
65. Olearchyk AS. Gastric carcinoma. A critical review of 243 cases. Am J Gastroenterol 1978; 70: 25-45.
66. Thomas RL, Rice RP. Calcifying mucinous adenocarcinoma of the stomach. Radiology 1967; 878:1002-1003.
67. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric carcinoma:sensitivity of double-contrast barium studies. AJR Am J Roentgenol 1994; 162: 329-34.
68. Rubesin SE, Levine MS, Laufer I. Doublecontrast upper gastrointestinal radiography: a pattern approach for diseases of the stomach. Radiology 2008; 246: 33-48.
69. Thompson G, Somers S, Stevenson GW. Benign gastric ulcer: a reliable radiologic diagnosis AJR Am J Roentgenol 1983; 141: 331-3.
70. Levine MS, Creteur V, Kressel HY, Laufer I, Herlinger H. Benign gastric ulcers: diagnosis and follow-up with double-contrast radiography. Radiology 1987; 164: 9-13.
71. Carman RD. A new roentgen-ray sign of ulcerating gastric cancer. J Am Med Assoc 1921; 77:990-92.
72. Van De Velde CJH. Current role of surgery and multimodal treatment in localized gastric cancer. Ann Oncol 2008; 19: 93-98
73. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009; 472: 467-77.
74. Greene FL, Page DL, Balch CM, Fleming ID, Morrow M, eds. Stomach. In: AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer; 2002. p. 99-106.
75. Zali H, Rezaei-Tavirani M, Kariminia A, Yousefi R, Shokrgozar MA. Evaluation of Growth Inhibitory and Apoptosis Inducing Activity of Human Calprotectin on the Human Gastric Cell Line (AGS). Iranian Biomedical Journal 2008; 12: 7-14.
76. Rezaei Tavirani M, Zali H, Nasiri S, Shokrgozar MA. Human Calprotectin, a Potent Anticancer with Minimal Side Effect. IJCP 2009; 2: 76-84.